ERJ Open Research
Riociguat versus Selexipag in Treatment-naïve CTEPH: an Exploratory Randomised Trial
By Yoshihisa Nakano, Fumie Kinoshita, Tomomi Sugiyama and 6 others.
Abstract
Extract Chronic thromboembolic pulmonary hypertension (CTEPH) is characterised by organised thrombi in the pulmonary arteries and secondary distal pulmonary vasculopathy [1, 2]. Multimodal treatment has improved prognosis [1, 2]; pulmonary endarterectomy (PEA) is recommended for surgically accessible CTEPH, whereas balloon pulmonary angioplasty (BPA) is indicated for distal disease or persistent/recurrent pulmonary hypertension (PH) after PEA [1–4]. Pharmacological therapy is also a key component of multimodal treatment [1, 2, 5–9].
Keywords
- Pulmonary Hypertension Research and Treatments
- Open access
Source
Published in ERJ Open Research. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.